AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$GKOS

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M (NYSE:GKOS)

Glaukos (GKOS) reported Q3 2026 net sales of $211M, up 58% YoY. The company raised its 2026 net sales guidance to $775M-$785M and projected $1B revenue for 2027, according to Chairman & CEO Thomas Burns.

Original reporting
seekingalpha.com
Published Oct 29, 2026, 2:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GKOS
Bullish
high confidence
Mentioned
$GKOS
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The guidance increase signals stronger market demand for Glaukos' glaucoma treatments, likely prompting buying interest.

02

Market read

First‑report earnings guidance lift for a mid‑cap biotech, offering a clear trading catalyst.

03

What to watch

Potential regulatory or reimbursement risks could temper upside despite the guidance lift.

Relevance 7/10Novelty 8/10Timing: after‑hours

Background

Glaukos (GKOS) reported record Q3 2026 net sales and raised its full‑year sales outlook.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Glaukos raised its full‑year 2026 net‑sales guidance to $775M‑$785M after reporting $211M Q3 sales.

Expected impact

likely upside as investors price in higher revenue outlook

Evidence & confidence

The company posted record Q3 sales and increased guidance, a material new data point that typically supports a price rally.

Market effects

Sector

Higher guidance may lift peers in the ophthalmic devices sector.

Regional

U.S. biotech/medical device market could see modest buying pressure.

Global

Limited to investors focused on specialty medical device stocks.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • Company
    Glaukos

    U.S. ophthalmic device maker

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

4 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com